INTEGRAL ANALYSIS OF GENOMIC AND TRANSCRIPTOMIC CHANGES IN CLEAR CELL RENAL CELL CARCINOMA IN THE RUSSIAN POPULATION

Renal cell carcinoma (Rcc) is the most common form of kidney cancer, accounting for about 90 % of cancers in the kidney. clear cell renal cell carcinoma (ccRcc) is the most common histological type of Rcc. clear cell renal cell carcinoma is characterized by specific genomic and transcriptomic aberrations in the tumor. We performed a targeted sequencing of key oncogenes and a genome-wide expression study in 58 patients with Rcc belonging to a population of the western part of the Russian Federation. the integrative analysis of genomics and transcriptome data revealed that the NFkβ nuclear complex, ERBB2 receptor, and tP53 transcription factor were the key regulators of observed changes in the expression. We also carried out the analysis of the mutational landscape in key genes associated with cancer. We found the difference in the molecular mechanisms of Rcc between different populations, since the detected expression regulators were not previously described as expression mediators in Rcc. since the ERBB2 receptor is a highly attractive target for therapeutic interventions of breast cancer, we will eventually be able to develop new treatment modalities for Rcc.

cancer, microarrays, mutations, genome, transcript, renal cell carcinoma, kidney cancer

1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424. doi:10.3322/caac.21492.

2. Bazzi W.M., Sjoberg D.D., Feuerstein M.A., Maschino A., Verma S., Bernstein M., O’Brien M.F., Jang T., Lowrance W., Motzer R.J., Russo P. Long-Term Survival Rates after Resection for Locally Advanced Kidney Cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 Experience. J Urol. 2015 Jun; 193(6): 1911–6. doi: 10.1016/j.juro.2014.12.022.

3. Wu X., Shu X. Epidemiology of Renal Cell Carcinoma. Renal Cell Carcinoma. Tokyo: Springer Japan; 2017: 1–18. doi: 10.1007/978-4-431-55531-5_1.

4. Cheville J.C., Lohse C.M., Zincke H., Weaver A.L., Blute M.L. Comparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma. Am J Surg Pathol. 2003; 27(5): 612–624. doi: 10.1097/00000478-200305000-00005.

5. Kume H., Takahashi S., Teramoto S., Isurugi K. Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention. BJU Int. 2001; 88(7): 804–804. doi: 10.1046/j.1464-410-X.2001.2505b.x.

6. Choueiri T.K., Je Y., Cho E. Analgesic use and the risk of kidney cancer: A meta-analysis of epidemiologic studies. Int J Cancer. 2014 Jan 15; 134(2): 384–96. doi: 10.1002/ijc.28093.

7. Ridge C., Pua B., Madoff D. Epidemiology and Staging of Renal Cell Carcinoma. Semin Intervent Radiol. 2014; 31(01): 003–008. doi:10.1055/s-0033-1363837.

8. Moch H., Cubilla A.L., Humphrey P.A., Reuter V.E., Ulbright T.M. WHO classification of tumours of the urinary system and male genital organs. Eur Urol. 2016 Jul; 70(1): 93–105. doi: 10.1016/j.eururo.2016.02.029.

9. Gossage L., Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol. 2010 May; 7(5): 277–88. doi: 10.1038/nrclinonc.2010.42.

10. Cheng L., Zhang S., MacLennan G.T., Lopez-Beltran A., Montironi R. Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol. 2009; 40(1): 10–29. doi: 10.1016/j.humpath.2008.09.009.

11. Ricketts C.J., De Cubas A.A., Fan H., Smith C.C., Lang M., Reznik E., Bowlby R., Gibb E.A., Akbani R., Beroukhim R., Bottaro D.P., Choueiri T.K., Gibbs R.A., Godwin A.K., Haake S., Hakimi A.A., Henske E.P., Hsieh J.J., Ho T.H., Kanchi R.S., Krishnan B., Kwiatkowski D.J., Lui W., Merino M.J., Mills G.B., Myers J., Nickerson M.L., Reuter V.E., Schmidt L.S., Shelley C.S., Shen H., Shuch B., Signoretti S., Srinivasan R., Tamboli P., Thomas G., Vincent B.G., Vocke C.D., Wheeler D.A., Yang L., Kim W.Y., Robertson A.G.; Cancer Genome Atlas Research Network, Spellman P.T., Rathmell W.K., Linehan W.M. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018 Jun 19; 23(12): 3698. doi: 10.1016/j.celrep.2018.06.032.

12. Sato Y., Yoshizato T., Shiraishi Y., Maekawa S., Okuno Y., Kamura T., Shimamura T., Sato-Otsubo A., Nagae G., Suzuki H., Nagata Y., Yoshida K., Kon A., Suzuki Y., Chiba K., Tanaka H., Niida A., Fujimoto A., Tsunoda T., Morikawa T., Maeda D., Kume H., Sugano S., Fukayama M., Aburatani H., Sanada M., Miyano S., Homma Y., Ogawa S. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013 Aug; 45(8): 860–7. doi: 10.1038/ng.2699.

13. Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E., Fennell T., O’Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B., Tukiainen T., Birnbaum D.P., Kosmicki J.A., Duncan L.E., Estrada K. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016 Aug 18; 536(7616): 285–91. doi: 10.1038/nature19057.

14. McLaren W., Gil L., Hunt S.E., Riat H.S., Ritchie G.R., Thormann A., Flicek P., Cunningham F. The Ensembl Variant Effect Predictor. Genome Biol. 2016 Jun 6; 17(1): 122. doi: 10.1186/s13059-016-0974-4.

15. Danecek P., Auton A., Abecasis G., Albers C.A., Banks E., DePris-to M.A., Handsaker R.E., Lunter G., Marth G.T., Sherry S.T., McVean G., Durbin R.; 1000 Genomes Project Analysis Group. The variant call format and VCFtools. Bioinformatics. 2011; 27(15): 2156–8. doi: 10.1093/bioinformatics/btr330.

16. Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., Mueller R., Nolan T., Pfaffl M.W., Shipley G.L., Vandesompele J., Wittwer C.T. The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments. Clin Chem. 2009 Apr; 55(4): 611–22. doi: 10.1373/clinchem.2008.112797.

17. Charlesworth B. Population Genetics. Encyclopedia of Biodiversity. Elsevier; 2013: 182–198. doi:10.1016/B978-0-12-384719-5.00116-7.

18. Solodskikh S.A., Panevina A.V., Gryaznova M.V., Gureev A.P., Serzhantova O.V., Mikhailov A.A., Maslov A.Y., Popov V.N. Targeted sequencing to discover germline variants in the BRCA1 and BRCA2 genes in a Russian population and their association with breast cancer risk. Mutat Res. 2019 Jan; 813: 51–57. doi: 10.1016/j.mrfmmm.2018.12.005.

19. Brugarolas J. Molecular Genetics of Clear-Cell Renal Cell Carcinoma. J Clin Oncol. 2014 Jun 20; 32(18): 1968–76. doi: 10.1200/JCO.2012.45.2003.

20. Serasanambati M., Chilakapati S.R. Function of Nuclear Factor Kappa B (NF-kB) in Human Diseases-A Review. South Indian J Biol Sci. 2016; 2(4): 368. doi: 10.22205/sijbs/2016/v2/i4/103443.

21. Iqbal N., Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014; 2014: 852748. doi: 10.1155/2014/852748.

22. Krishnamurti U., Silverman J.F. HER2 in Breast Cancer. Adv Anat Pathol. 2014 Mar; 21(2): 100–7. doi: 10.1097/PAP.0000000000000015.

23. Kümler I., Tuxen M.K., Nielsen D.L. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev. 2014 Mar; 40(2): 259–70. doi: 10.1016/j.ctrv.2013.09.002.

24. Bronchud M.H., Castillo S., Escriva de Romaní S., Mourelo S., Fernández A., Baena C., Murillo J., Julia J.C., Esquius J., Romero R., Andreu X. HER2 Blockade in Metastatic Collecting Duct Carcinoma (CDC) of the Kidney: A Case Report. Onkologie. 2012; 35(12): 776–9. doi: 10.1159/000345041.

25. Shen C., Kaelin W.G. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 2013 Feb; 23(1): 18–25. doi: 10.1016/j.semcancer.2012.06.001.